Non-Langerhans Cell Histiocytosis

This is a group of rare diseases where the body makes too many histiocytes, which are a type of immune cell. These histiocytes are not the specific type called Langerhans cells. It can affect different parts of the body, like the bones, skin, or lymph nodes.

Condition

What people with Non-Langerhans Cell Histiocytosis report

Every report comes from a Lived member, sent anonymously.

Have you tried Zelboraf (Vemurafenib) for Non-Langerhans Cell Histiocytosis?

NameHow it went

About Non-Langerhans Cell Histiocytosis

What It Is

Non-Langerhans cell histiocytosis is an umbrella term for a group of rare disorders in which histiocytes, immune cells related to macrophages and dendritic cells, build up in tissues where they do not belong. These collections can form bumps in the skin, enlarge lymph nodes, or infiltrate bones and internal organs. The problems they cause depend on where the cells settle and how much tissue they affect. The name separates these disorders from Langerhans cell histiocytosis, which involves a different cell type, and the group itself spans very different diseases. Juvenile xanthogranuloma usually appears in infancy as yellow-orange skin bumps that fade on their own. Rosai-Dorfman disease most often causes large lymph nodes, commonly in the neck, in children and young adults. Erdheim-Chester disease is a multisystem condition of adults, usually in their 50s or 60s, that can affect the long bones, heart, tissue around the kidneys and brain. Xanthoma disseminatum and multicentric reticulohistiocytosis mainly affect the skin, the lining of the mouth, throat and eyes, or the joints. A small number of malignant forms, such as histiocytic sarcoma, behave like aggressive cancers. Some medical classifications also list hemophagocytic lymphohistiocytosis (HLH) and inherited lipid storage diseases such as Niemann-Pick disease under this heading. These are distinct illnesses: HLH is an acute, often life-threatening overreaction of the immune system, and Niemann-Pick diseases are inherited metabolic disorders. Each is described separately.

Causes & Risk Factors

The causes are only partly understood, but research over the past decade has changed how these disorders are seen. Many of them, including Erdheim-Chester disease and some cases of Rosai-Dorfman disease, are driven by genetic changes acquired in the abnormal cells themselves. These changes most often affect the MAPK pathway, a chain of signals that tells cells when to grow and become active. A common example is a change in the BRAF gene called BRAF V600E. Because the changes arise in the affected cells during life, they are not the kind of gene variant a person inherits from a parent. This finding led experts to classify Erdheim-Chester and Rosai-Dorfman disease as neoplasms, meaning abnormal growths of cells, even though most behave far more slowly than typical cancers. Age patterns differ by type. Juvenile xanthogranuloma appears within the first year of life in about three of every four cases, Rosai-Dorfman disease is most common in children and young adults, and Erdheim-Chester disease mainly affects adults in later middle age. Some forms occur alongside other illnesses. Rosai-Dorfman disease can appear with autoimmune diseases or cancers, and multicentric reticulohistiocytosis often coexists with a cancer or an autoimmune disease, which is one reason doctors look carefully for related conditions after diagnosis.

How It's Diagnosed

Because these disorders are rare and their symptoms overlap with many common conditions, diagnosis is often delayed. This is especially true of Erdheim-Chester disease, which develops gradually and can resemble many other illnesses. The key step is a biopsy, a small sample of the affected skin, lymph node, bone or other tissue. A pathologist examines the cells under a microscope and uses special stains to identify the type of histiocyte, which separates these disorders from Langerhans cell histiocytosis, reactive inflammation and other cancers. The tissue is usually also tested for genetic changes such as BRAF V600E. The result can support the diagnosis and shows whether a targeted medicine is likely to work. Doctors then look at how far the disease extends, a step similar to staging in cancer. Adults often have a whole-body PET-CT scan, an imaging test that highlights active disease. In Erdheim-Chester disease, imaging shows dense, thickened bone around both knees in about 90 percent of people, a pattern that strongly points to the diagnosis. Blood tests check blood counts and organ function, and a bone marrow sample is examined if blood counts are abnormal. For an infant with skin bumps only and no other symptoms, basic blood tests and an eye examination may be enough.

Treatment Options

Treatment depends on the type, where the disease is and whether it is causing harm, and not everyone needs it. The skin bumps of juvenile xanthogranuloma usually fade over several years without treatment. People who have no symptoms and limited disease that does not involve critical organs may be monitored closely instead of treated. A single troublesome lesion can sometimes be removed surgically, although lesions of xanthoma disseminatum often return after removal. Rosai-Dorfman disease can often be observed or treated locally. When the disease affects vital organs or keeps progressing, medicine is usually needed, and most people with Erdheim-Chester disease need treatment. Targeted medicines that block the overactive growth signal are now preferred for Erdheim-Chester disease, chosen according to the genetic change found in the tissue. Vemurafenib (Zelboraf), a BRAF inhibitor, is approved in the US for Erdheim-Chester disease with a BRAF V600 change, and cobimetinib (Cotellic), which blocks MEK, a protein further along the same signaling chain, is approved for adults with histiocytic neoplasms. Many people improve substantially, although improvement can take a year or more to reach its fullest and responses are less reliable when no genetic change is found. These are pills taken over the long term, because the disease comes back in roughly three of every four people who stop them. Side effects are common and lead many people to lower the dose or stop over time, so the care team monitors treatment closely. Other options include chemotherapy drugs such as cladribine or cytarabine given for a set period, interferon, and medicines that calm inflammation. Some types have their own approaches: multicentric reticulohistiocytosis is treated with anti-inflammatory medicines and, in some reports, biologic drugs that block a signaling protein called TNF, while xanthoma disseminatum may first be treated with cholesterol-lowering medicines when whole-body treatment is needed. Children are less often given targeted drugs because of the long treatment they require, and the rare malignant forms are treated as cancers, with surgery and sometimes radiation when the disease is confined to one place. For several types, the evidence comes mainly from small studies and case reports, so treatment plans are often individualized.

What to Expect

The outlook varies more across this group than within most single diagnoses. Juvenile xanthogranuloma limited to the skin is usually harmless and disappears over years. Many cases of Rosai-Dorfman disease stay limited, although some people with widespread or stubborn disease become seriously ill. Erdheim-Chester disease is typically a long-term condition that can often be controlled, but treatment is usually ongoing. Spontaneous improvement has been reported in every type, while the malignant forms carry a much more serious outlook when they have spread. Even slow-growing forms can weigh heavily on daily life when they involve important organs, so the burden depends largely on where the disease is. Damage that occurs before diagnosis, such as to the pituitary gland or kidneys, may not fully reverse. Follow-up usually includes periodic imaging and blood tests to see whether the disease is active and whether treatment is working, along with checks for medicine side effects. People with Erdheim-Chester disease need long-term follow-up partly because a related bone marrow cancer occasionally develops. Because these conditions are rare, knowledge about long-term outcomes is still limited, and much of it comes from registries and specialist centers.

When to Seek Help

See a doctor about skin bumps that are yellow, orange or reddish-brown and keep multiplying or growing, or lymph nodes that stay enlarged. Constant thirst and passing large amounts of urine can mean the disease has affected the pituitary gland, and should be reported to the care team. For a young child with juvenile xanthogranuloma, a red or cloudy eye, blood visible in the front of the eye or a new spot on the colored part of the eye needs same-day assessment by an eye specialist, because eye involvement can lead to glaucoma and vision loss. Hoarseness, noisy breathing or trouble swallowing in someone with lesions in the mouth or throat needs prompt contact with the care team, because the lesions can narrow the airway. Struggling to breathe is an emergency that warrants calling 911.

Questions to Ask Your Doctor

  1. 1.Which specific type of histiocytosis do I have, and what does that mean for the outlook?
  2. 2.Has my tissue been tested for BRAF or other genetic changes, and do the results make targeted treatment an option?
  3. 3.Is close monitoring reasonable for me, or are any organs affected enough to need treatment now?
  4. 4.If I start a targeted medicine, how long would I take it and which side effects should we watch for?
  5. 5.Do you work with a center that regularly treats histiocytic disorders?

Last reviewed • Oct 2026

Educational content, not medical advice.